Pacira BioSciences, Inc.
Pacira BioSciences develops, manufactures, markets, and sells non-opioid pain management solutions. Products include EXPAREL, ZILRETTA, and iovera system. The company has a development agreement with Aratana Therapeutics for NOCITA. Pacira was previously known as Pacira Pharmaceuticals before changing its name in 2019.
Overview
Strengths
- Asset-light, cash-generative model: capital expenditure takes only 4.1% of revenue and free cash flow was positive in each of the last 6 years.
- Valued below its Drug Manufacturers - Specialty & Generic peers: P/FCF 11.0x vs. a median of 21.4x.
- Consistent growth: revenue has compounded at 11.1% a year over 5 years, rising every year.
- Shareholder-friendly capital allocation: the share count has shrunk by 3.6% a year over the last three years through buybacks.
- Improving fundamentals over the last year: return on assets up 7.0 points, gross margin up 3.7 points and asset turnover up 27.3%.
- Cheaper than its own history: P/FCF 11.0x vs. a historical average of 24.1x.
Weaknesses
- Heavy interest burden: interest expense absorbs 46% of operating profit.
- Our discounted cash flow target price (22.90 USD) is 37% below the current price.
- Unstable profitability: operating margin ranged from 3% to 25% over the last 6 years.
- Earnings are projected to decline (-10.0% per year).
Key Financial Data